Evidence map›Paper›PMID 40027989›Full record

ArticleVaccine: X2025

Costs estimation of three models of COVID-19 vaccination in Beijing, China.

Hongzeng Wang, Dan Zhao, Xiaomei Li, Luodan Suo, Li Lu, Zhujiazi Zhang

Abstract read
In one paragraph

Article in Vaccine: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongzeng WangHospital Administration Department, Beijing United Family Hospital, Beijing 100015, China.
Dan ZhaoDepartment of Immunization and Prevention, Beijing Center for Disease Control and Prevention, Beijing 100013, China.
Xiaomei LiDepartment of Immunization and Prevention, Beijing Center for Disease Control and Prevention, Beijing 100013, China.
Luodan SuoDepartment of Immunization and Prevention, Beijing Center for Disease Control and Prevention, Beijing 100013, China.
Li LuDepartment of Immunization and Prevention, Beijing Center for Disease Control and Prevention, Beijing 100013, China.
Zhujiazi ZhangDepartment of Immunization and Prevention, Beijing Center for Disease Control and Prevention, Beijing 100013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the emergency use authorization for the COVID-19 vaccine in 2021, the Chinese government has used three vaccination models: vaccination clinic, mass vaccination center, and door-to-door service. This study compared these three different models, focusing on costs, and implementation in each vaccination strategy. A cross-sectional study, conducted during the COVID-19 vaccination campaign from January 1 to 20, 2021, utilized a questionnaire to collect data on vaccination sites and conducted a random sample costs analysis of three models. Data on costs, including construction, materials, labor, and operations, were gathered through interviews and field surveys to understand resource utilization and personnel involvement in vaccination activities. Beijing's COVID-19 vaccination campaign involved 580 locations administering 1,829,324 doses. The numbers of vaccination clinics, mass vaccination centers, and door-to-door service were 233, 137, and 210. The total doses administered at vaccination clinics, mass vaccination centers, and door-to-door service numbered 465,721 (25.5 %), 991,444 (54.2 %), and 372,159 (20.3 %), respectively. The median daily doses administered at vaccination clinics, mass vaccination centers, and door-to-door service were 124, 453, and 540, respectively. The daily costs of the vaccination clinic, mass vaccination center, and door-to-door service were $4644.1, $22,746.5, and $4109.6, respectively, and the costs per dose were $12.9, $10.5, and $7.4, respectively. We concluded that there are significant variations in costs and efficiency across the three vaccination models. We must comprehensively consider the available regional resources, the target population for vaccination, the expected vaccination effect, and other factors to choose an appropriate vaccination model.

Indexed as

Costs analysisCOVID-19Mass vaccinationVaccination models

Identifiers

PMID40027989
PMCPMC11872071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.